Reading and Resources

• Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone in paitents with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096-2107. https://pubmed.ncbi.nlm.nih.gov/31735560/
• Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2024;42:2702-2712. https://pubmed.ncbi.nlm.nih.gov/38879802/
• Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232-2244. https://pubmed.ncbi.nlm.nih.gov/36507686/
• D’Souza A, Shah N, Rodriguez C, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2022;40:3576-3586. https://pubmed.ncbi.nlm.nih.gov/36029527/
• De Novellis D, Fontana R, Giudice V, et al. Innovative anti-CD38 and anti-BCMA targeted therapies in multiple myeloma: Mechanisms of action and resistance. Int J Mol Sci. 2022;24:645. https://pubmed.ncbi.nlm.nih.gov/36614086/
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319-1331. https://pubmed.ncbi.nlm.nih.gov/27705267/
• Dimopoulos MA, Oriol A, Nahi H, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial. J Clin Oncol. 2023;41:1590-1599. https://pubmed.ncbi.nlm.nih.gov/36599114/
• Dimopoulos MA, Richardson P, Lonial S. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22:460-473. https://pubmed.ncbi.nlm.nih.gov/35148975/
• Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet. 2020;396:1563-1573. https://pubmed.ncbi.nlm.nih.gov/33189178/
• Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259-2267. https://pubmed.ncbi.nlm.nih.gov/37582952/
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621-631. https://pubmed.ncbi.nlm.nih.gov/26035255/
• Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265-1274. https://pubmed.ncbi.nlm.nih.gov/35658469/
• Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397:2361-2371. https://pubmed.ncbi.nlm.nih.gov/34097854/
• Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495-505. https://pubmed.ncbi.nlm.nih.gov/35661166/
• Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705-716. https://pubmed.ncbi.nlm.nih.gov/33626253/
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754-766. https://pubmed.ncbi.nlm.nih.gov/27557302/
• Sammartano V, Franceschini M, Fredducci S, et al. Anti-BCMA novel therapies for multiple myeloma. Cancer Drug Resist. 2023;6:169-181. https://pubmed.ncbi.nlm.nih.gov/37065871/
• Swan D, Murphy P, Glavey S, Quinn J. Bispecific antibodies in multiple myeloma: Opportunities to enhance efficacy and improve safety. Cancers (Basel). 2023;15:1819. https://pubmed.ncbi.nlm.nih.gov/36980705/

All URLs accessed August 30, 2024